These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 34825292)

  • 61. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
    O'Rourke DM; Nasrallah MP; Desai A; Melenhorst JJ; Mansfield K; Morrissette JJD; Martinez-Lage M; Brem S; Maloney E; Shen A; Isaacs R; Mohan S; Plesa G; Lacey SF; Navenot JM; Zheng Z; Levine BL; Okada H; June CH; Brogdon JL; Maus MV
    Sci Transl Med; 2017 Jul; 9(399):. PubMed ID: 28724573
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Glioblastoma, an opportunity T cell trafficking could bring for the treatment.
    Karimi-Shahri M; Khorramdel M; Zarei S; Attarian F; Hashemian P; Javid H
    Mol Biol Rep; 2022 Oct; 49(10):9863-9875. PubMed ID: 35604627
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
    Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
    Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
    Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
    Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
    [TBL] [Abstract][Full Text] [Related]  

  • 65. B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma.
    Tang X; Zhao S; Zhang Y; Wang Y; Zhang Z; Yang M; Zhu Y; Zhang G; Guo G; Tong A; Zhou L
    Mol Ther Oncolytics; 2019 Sep; 14():279-287. PubMed ID: 31485480
    [TBL] [Abstract][Full Text] [Related]  

  • 66. New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy.
    Wu WT; Lin WY; Chen YW; Lin CF; Wang HH; Wu SH; Lee YY
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673696
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacological strategies for improving the prognosis of glioblastoma.
    Raj D; Agrawal P; Gaitsch H; Wicks E; Tyler B
    Expert Opin Pharmacother; 2021 Oct; 22(15):2019-2031. PubMed ID: 34605345
    [No Abstract]   [Full Text] [Related]  

  • 68. Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma.
    Mooney J; Bernstock JD; Ilyas A; Ibrahim A; Yamashita D; Markert JM; Nakano I
    World Neurosurg; 2019 Sep; 129():90-100. PubMed ID: 31152883
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Progression in chimeric antigen receptor T (CAR-T) cell therapy of solid tumors: A review].
    Fang Z; Han H; Liang L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Oct; 35(10):944-948. PubMed ID: 31814572
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy.
    Pellegatta S; Savoldo B; Di Ianni N; Corbetta C; Chen Y; Patané M; Sun C; Pollo B; Ferrone S; DiMeco F; Finocchiaro G; Dotti G
    Sci Transl Med; 2018 Feb; 10(430):. PubMed ID: 29491184
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma.
    Schmidts A; Srivastava AA; Ramapriyan R; Bailey SR; Bouffard AA; Cahill DP; Carter BS; Curry WT; Dunn GP; Frigault MJ; Gerstner ER; Ghannam JY; Kann MC; Larson RC; Leick MB; Nahed BV; Richardson LG; Scarfò I; Sun J; Wakimoto H; Maus MV; Choi BD
    Neurooncol Adv; 2023; 5(1):vdac185. PubMed ID: 36751672
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Navigating the Immune Challenge in Glioblastoma: Exploring Immunotherapeutic Avenues for Overcoming Immune Suppression.
    Jain P; Vashist S; Panjiyar BK
    Cureus; 2023 Sep; 15(9):e46089. PubMed ID: 37900496
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical utility of CAR T cell therapy in brain tumors: Lessons learned from the past, current evidence and the future stakes.
    Chatterjee A; Asija S; Yadav S; Purwar R; Goda JS
    Int Rev Immunol; 2022; 41(6):606-624. PubMed ID: 36191126
    [TBL] [Abstract][Full Text] [Related]  

  • 74. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
    Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
    J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
    [TBL] [Abstract][Full Text] [Related]  

  • 75. CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience.
    Palomba ML; Qualls D; Monette S; Sethi S; Dogan A; Roshal M; Senechal B; Wang X; Rivière I; Sadelain M; Brentjens RJ; Park JH; Smith EL
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35173030
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors.
    Han S; Latchoumanin O; Wu G; Zhou G; Hebbard L; George J; Qiao L
    Cancer Lett; 2017 Apr; 390():188-200. PubMed ID: 28089834
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
    Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
    PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Engineering Chimeric Antigen Receptor T cells to Treat Glioblastoma.
    Choi BD; O'Rourke DM; Maus MV
    J Target Ther Cancer; 2017 Aug; 6(4):22-25. PubMed ID: 29167820
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Therapeutic potential of CAR T cell in malignancies: A scoping review.
    Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
    Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.